ImmuCell (NASDAQ:ICCC – Get Free Report) and Ayr Wellness (OTCMKTS:AYRWF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and price targets for ImmuCell and Ayr Wellness, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmuCell | 1 | 0 | 0 | 0 | 1.00 |
| Ayr Wellness | 0 | 0 | 0 | 0 | 0.00 |
Earnings and Valuation
This table compares ImmuCell and Ayr Wellness”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmuCell | $27.64 million | 3.63 | -$1.04 million | ($0.06) | -184.67 |
| Ayr Wellness | $463.63 million | 0.00 | -$359.31 million | ($1.62) | -0.01 |
ImmuCell has higher earnings, but lower revenue than Ayr Wellness. ImmuCell is trading at a lower price-to-earnings ratio than Ayr Wellness, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
ImmuCell has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Ayr Wellness has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.
Profitability
This table compares ImmuCell and Ayr Wellness’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmuCell | -1.82% | -1.88% | -1.22% |
| Ayr Wellness | N/A | N/A | N/A |
Institutional & Insider Ownership
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 0.9% of Ayr Wellness shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 8.1% of Ayr Wellness shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Ayr Wellness beats ImmuCell on 7 of the 12 factors compared between the two stocks.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
About Ayr Wellness
Ayr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
